Brazil - Technology for monoclonal antibodies

This is a business opportunity from an overseas buyer. Pitch for the business and explain how your company meets their requirements.

A research agency is looking for partners to co-develop innovative immune system improver technology.


Opportunity closing date
01 July 2018
Opportunity publication date
06 April 2018
Opportunity type
Public Sector
Biotechnology & Pharmaceuticals, Healthcare & Medical
Enquiries received
Value of contract
to be confirmed
Your guide to exporting
Report opportunity


You should be able and willing to co-develop and out license immune system improver technology.

It is directed to suppress infections caused by Methicillin-Resistant Staphylococcus Aureus (MRSA).

The technology produces monoclonal antibodies capable of recognising and binding to proteins.

The out licensing can be exclusive or non exclusive.

The co-development can occur in the UK.

Submit your proposal to the Department for International Trade team in Brazil.

All submissions will be reviewed and you will be notified of any potential next steps. You can only submit a proposal if you are a UK registered company.

Opportunity closing date
01 July 2018
Value of contract
to be confirmed

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?